Gilde Healthcare Partners

Gilde Healthcare Partners

Gilde Healthcare Partners was established in 2009 when Pieter van der Meer and Geert-Jan Mulder led a carve-out of the healthcare activities from Gilde Investment Management, the Dutch private equity firm founded in 1982. The separation created a sector-specialist with a single mandate: invest exclusively in healthcare companies across venture, growth, and mature buyout stages. The firm operates from Utrecht with additional offices in Frankfurt and Cambridge, Massachusetts — a deliberate transatlantic footprint designed to bridge European healthcare innovation with US market access. The firm runs a dual-fund structure that covers the full company lifecycle. Gilde Healthcare Venture & Growth invests in early- to late-stage companies developing medical devices, digital health platforms, and diagnostics, targeting commercial-stage businesses with regulatory clearances. Gilde Healthcare Private Equity targets profitable, mature healthcare services and medtech companies with buy-and-build strategies. Confirmed portfolio positions include Symphogen, a Danish antibody therapeutics company sold to Servier in 2015, and ClearData, a US-based healthcare cloud security firm. The geographic mandate spans the Benelux, DACH region, Nordics, United Kingdom, and the United States. As of its most recent fund closing, Gilde Healthcare Private Equity V reached €557 million in 2024, exceeding its €500 million target (per the firm, 2024). The venture and growth fund has been active across multiple vintages, with the firm managing total commitments above €1.4 billion. The Cambridge office, led by Arthur Franken, serves as the beachhead for portfolio companies entering North American markets. Team members maintain active board roles and operational involvement in portfolio companies, reflecting a hands-on investment style rather than passive monitoring. The structural differentiator is a unified partnership that deploys capital on both sides of the regulatory approval line — venture funding for clinical and regulatory milestones, growth equity for commercial scaling, and private equity for mature profitability — all under one roof. This continuum allows portfolio companies to stay within the same capital ecosystem without forced ownership transitions at each stage gate. The succession path was embedded from inception, with Edwin de Graaf formally moving into the Managing Partner group in 2012, establishing a multi-generational leadership model that survived the original Gilde separation.